Anebulo Pharmaceuticals(ANEB)

Focus: Anebulo Pharmaceuticals is a public-stage biotech company founded in 2020 focused on cannabinoid overdose and acute intoxication treatments in the neurology space. The company operates as a pre-revenue entity with a highly specialized therapeutic focus.

Neurology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Anebulo Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Anebulo Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

THC

Acute Cannabis-induced CNS Depression

N/A

Clinical Trials (2)

NCT05282797Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test

Phase 2

Help build intelligence for Anebulo Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

First-mover advantage in an emerging therapeutic area (cannabinoid overdose) with growing clinical relevance as cannabis legalization expands — limited competitive landscape
Public company status (ticker: ANEB) provides equity upside potential and access to capital markets for salary/bonus structures
Small, focused pipeline allows individual contributors to have outsized impact on company direction and clinical strategy

Watch Out For

Zero active job openings and no hiring momentum suggests minimal expansion or potential organizational contraction ahead
Severe cash burn: $8.2M net loss in FY2025 on only $4M R&D spend, with cash declining from $11M to $3M YoY — runway concerns within 12-18 months
No marketed products, no revenue, and only Phase 2 advancement (selonabant) — 5+ years minimum to potential approval and cash inflection
Niche indication (acute cannabinoid intoxication) has uncertain commercial market size and payer acceptance compared to large primary care indications

Generated by Claude from Anebulo Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT06017622Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression

N/A

selonabant

Acute Cannabinoid Intoxication

Phase 2

Clinical Trials (1)

NCT07211607I.V. Selonabant in Healthy Adult Subjects

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2020

Portfolio: 3 clinical trials

Top TAs: Neurology

SEC Filings: 2 available

Therapeutic Area Focus

Neurology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$4M37%

Net Income

-$8M

Cash

$3M

Source: SEC 10-K Filing

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo